308 related articles for article (PubMed ID: 28583174)
1. Follistatin is a metastasis suppressor in a mouse model of HER2-positive breast cancer.
Seachrist DD; Sizemore ST; Johnson E; Abdul-Karim FW; Weber Bonk KL; Keri RA
Breast Cancer Res; 2017 Jun; 19(1):66. PubMed ID: 28583174
[TBL] [Abstract][Full Text] [Related]
2. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
3. Increased Expression of Follistatin in Breast Cancer Reduces Invasiveness and Clinically Correlates with Better Survival.
Zabkiewicz C; Resaul J; Hargest R; Jiang WG; Ye L
Cancer Genomics Proteomics; 2017; 14(4):241-251. PubMed ID: 28647698
[TBL] [Abstract][Full Text] [Related]
4. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
5. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice.
Ogino H; Yano S; Kakiuchi S; Muguruma H; Ikuta K; Hanibuchi M; Uehara H; Tsuchida K; Sugino H; Sone S
Clin Cancer Res; 2008 Feb; 14(3):660-7. PubMed ID: 18245525
[TBL] [Abstract][Full Text] [Related]
6. Dissociation of angiogenesis and tumorigenesis in follistatin- and activin-expressing tumors.
Krneta J; Kroll J; Alves F; Prahst C; Sananbenesi F; Dullin C; Kimmina S; Phillips DJ; Augustin HG
Cancer Res; 2006 Jun; 66(11):5686-95. PubMed ID: 16740706
[TBL] [Abstract][Full Text] [Related]
7. EDI3 knockdown in ER-HER2+ breast cancer cells reduces tumor burden and improves survival in two mouse models of experimental metastasis.
Glotzbach A; Rohlf K; Gonscharow A; Lüke S; Demirci Ö; Begher-Tibbe B; Overbeck N; Reinders J; Cadenas C; Hengstler JG; Edlund K; Marchan R
Breast Cancer Res; 2024 May; 26(1):87. PubMed ID: 38816770
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of activin A in oral squamous cell carcinoma: association with poor prognosis and tumor progression.
Chang KP; Kao HK; Liang Y; Cheng MH; Chang YL; Liu SC; Lin YC; Ko TY; Lee YS; Tsai CL; Wang TH; Hao SP; Tsai CN
Ann Surg Oncol; 2010 Jul; 17(7):1945-56. PubMed ID: 20309641
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.
O'Neal J; Clem A; Reynolds L; Dougherty S; Imbert-Fernandez Y; Telang S; Chesney J; Clem BF
Breast Cancer Res Treat; 2016 Nov; 160(1):29-40. PubMed ID: 27613609
[TBL] [Abstract][Full Text] [Related]
10. HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer.
Hosonaga M; Arima Y; Sampetrean O; Komura D; Koya I; Sasaki T; Sato E; Okano H; Kudoh J; Ishikawa S; Saya H; Ishikawa T
Int J Mol Sci; 2018 Jul; 19(8):. PubMed ID: 30042341
[TBL] [Abstract][Full Text] [Related]
11. In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
Basak P; Leslie H; Dillon RL; Muller WJ; Raouf A; Mowat MRA
Genes Chromosomes Cancer; 2018 Apr; 57(4):182-191. PubMed ID: 29218825
[TBL] [Abstract][Full Text] [Related]
12. Follistatin Expression in Human Invasive Breast Tumors: Pathologic and Clinical Associations.
Couto HL; Dela Cruz C; Buzelin MA; Toppa NH; Wainstein AJ; Reis FM
Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):108-112. PubMed ID: 27389553
[TBL] [Abstract][Full Text] [Related]
13. Role of the focal adhesion protein kindlin-1 in breast cancer growth and lung metastasis.
Sin S; Bonin F; Petit V; Meseure D; Lallemand F; Bièche I; Bellahcène A; Castronovo V; de Wever O; Gespach C; Lidereau R; Driouch K
J Natl Cancer Inst; 2011 Sep; 103(17):1323-37. PubMed ID: 21832234
[TBL] [Abstract][Full Text] [Related]
14. Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins.
Sidis Y; Mukherjee A; Keutmann H; Delbaere A; Sadatsuki M; Schneyer A
Endocrinology; 2006 Jul; 147(7):3586-97. PubMed ID: 16627583
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells.
Karve TM; Preet A; Sneed R; Salamanca C; Li X; Xu J; Kumar D; Rosen EM; Saha T
PLoS One; 2012; 7(6):e37697. PubMed ID: 22685544
[TBL] [Abstract][Full Text] [Related]
16. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
[TBL] [Abstract][Full Text] [Related]
17. Prolactin hormone exerts anti-tumorigenic effects in HER-2 overexpressing breast cancer cells through regulation of stemness.
Hachim IY; López-Ozuna VM; Hachim MY; Lebrun JJ; Ali S
Stem Cell Res; 2019 Oct; 40():101538. PubMed ID: 31450192
[TBL] [Abstract][Full Text] [Related]
18. OVOL2 antagonizes TGF-β signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis.
Wu RS; Hong JJ; Wu JF; Yan S; Wu D; Liu N; Liu QF; Wu QW; Xie YY; Liu YJ; Zheng ZZ; Chan EC; Zhang ZM; Li BA
Oncotarget; 2017 Jun; 8(24):39401-39416. PubMed ID: 28455959
[TBL] [Abstract][Full Text] [Related]
19. Lentivirus-Mediated Short Hairpin RNA for Follistatin Downregulation Suppresses Tumor Progression in Hypopharyngeal Carcinoma.
Ge L; Liu SF
Curr Med Sci; 2022 Aug; 42(4):832-840. PubMed ID: 35864413
[TBL] [Abstract][Full Text] [Related]
20. Stromal SNAI2 Is Required for ERBB2 Breast Cancer Progression.
Blanco-Gómez A; Hontecillas-Prieto L; Corchado-Cobos R; García-Sancha N; Salvador N; Castellanos-Martín A; Sáez-Freire MDM; Mendiburu-Eliçabe M; Alonso-López D; De Las Rivas J; Lorente M; García-Casas A; Del Carmen S; Abad-Hernández MDM; Cruz-Hernández JJ; Rodríguez-Sánchez CA; Claros-Ampuero J; García-Cenador B; García-Criado J; Orimo A; Gridley T; Pérez-Losada J; Castillo-Lluva S
Cancer Res; 2020 Dec; 80(23):5216-5230. PubMed ID: 33023950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
